Results 241 to 250 of about 2,337,722 (307)

Association of healthy lifestyle with incident cardiovascular diseases in individuals with type 1 diabetes mellitus: a prospective cohort study. [PDF]

Diabetol Metab Syndr
Wang Y, Liu J, Cao F, Wang Y, Li Z, Zeng H, Zhou M, He Q, Jiang W, Li Y, Yan J.   +10 more
europepmc   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Patient-Reported Receipt of Satisfactory Healthy Lifestyle Guidance and Associated Factors Among Outpatients in China: A Nationwide Cross-Sectional Survey. [PDF]

Healthcare (Basel)
Mi J, Liu Y.
europepmc   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang, Ana Soldo, Olgica Velkovski Škopić, Sunčana Vlah Tomičević, Tin Šaban, Andrej Belančić, Ana Jelaković, Josipa Josipović, Mihaela Marinović Glavić, Ivan Pećin, Luka Prgomet, Tajana Željković Vrkić, Bojan Jelaković   +12 more
wiley   +1 more source

Associations of Healthy Lifestyle With All-Cause and Cardiovascular Disease Mortality in Individuals With Cardiovascular-Kidney-Metabolic Syndrome: Two Prospective Cohort Studies. [PDF]

Clin Cardiol
You Q, Fu W, Xu M, Wu Y, Lett AM, Li X, Fan M, Xu S.   +7 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Adherence to Healthy Lifestyle and Risk of Cardiometabolic Diseases in Individuals With Hypertension.

JAMA Netw Open
Qiu Z, Liu G, Hu Y, Wang S, Liu B, Rimm EB, Wang M, Manson JE, Hu FB, Sun Q.   +9 more
europepmc   +1 more source

Effects of Teleintervention Maintenance Programs for Children (Age 6-12) and Adolescents (Age 13-18) With Overweight or Obesity-Promoting a Healthy Lifestyle: A Systematic Review. [PDF]

Pediatr Obes
Wittmann A, Späth P, Zocher F, Nagel E, Lauerer M, Schellenberg M.   +5 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source